Pharmacogenetic and pharmacogenomic discovery strategies

Abstract

Genetic/genomic profiling at a single-patient level is expected to provide critical information for determining inter-individual drug toxicity and potential efficacy in cancer therapy. A better definition of cancer subtypes at a molecular level, may correspondingly complement such pharmacogenetic and pharmacogenomic approaches, for more effective personalized treatments. Current pharmacogenetic/pharmacogenomic strategies are largely based on the identification of known polymorphisms, thus limiting the discovery of novel or rarer genetic variants. Recent improvements in cost and throughput of next generation sequencing (NGS) are now making whole-genome profiling a plausible alternative for clinical procedures. Beyond classical pharmacogenetic/pharmacogenomic traits for drug metabolism, NGS screening programs of cancer genomes may lead to the identification of novel cancer-driving mutations. These may not only constitute novel therapeutic targets, but also effector determinants for metabolic pathways linked to drug metabolism. An additional advantage is that cancer NGS profiling is now leading to discovering targetable mutations, e.g., in glioblastomas and pancreatic cancers, which were originally discovered in other tumor types, thus allowing for effective repurposing of active drugs already on the market.

Keywords

Pharmacogenetics / pharmacogenomics / cancer / next-generation sequencing / genomic variants

References

[1] Relli V,Guerra E.Distinct lung cancer subtypes associate to distinct drivers of tumor progression..Oncotarget2018;9:35528-40 PMCID:PMC6238974

[2] Ambrogi F,Querzoli P,Boracchi P.Molecular subtyping of breast cancer from traditional tumor marker profiles using parallel clustering methods..Clin Cancer Res2006;12:781-90

[3] Querzoli P,Rinaldi R,Biganzoli E.Axillary lymph node nanometastases are prognostic factors for disease-free survival and metastatic relapse in breast cancer patients..Clin Cancer Res2006;12:6696-701

[4] Querzoli P,Pedriali M,Ambrogi F.An immunohistochemically positive E-cadherin status is not always predictive for a good prognosis in human breast cancer..Br J Cancer2010;103:1835-9 PMCID:PMC3008612

[5] Biganzoli E,Ambrogi F,Lisboa P.p53 status identifies two subgroups of triple-negative breast cancers with distinct biological features..Jpn J Clin Oncol2011;41:172-9

[6] Tripaldi R,Alberti S.Human height genes and cancer..BBA reviews cancer2013;1836:27-41

[7] Zanna P,Vacca G,Palombo B.Trop-1 is a novel cell growth stimulatory molecule that marks early stages of tumor progression..Cancer2007;110:452-64

[8] Guerra E,Dell’ Arciprete R,Palombo B.A bi-cistronic CYCLIN D1-TROP2 mRNA chimera demonstrates a novel oncogenic mechanism in human cancer..Cancer Res2008;68:8113-21

[9] Guerra E,Tripaldi R,Simeone P.Trop-2 induces tumor growth through Akt and determines sensitivity to Akt inhibitors..Clin Cancer Res2016;22:4197-205

[10] Ambrogi F,Boracchi P,Relli V.Trop-2 is a determinant of breast cancer survival..PLoS One2014;9:e96993 PMCID:PMC4019539

[11] Guerra E,Aloisi AL,Vacca G.The Trop-2 signalling network in cancer growth..Oncogene2013;32:1594-600

[12] Trerotola M,Guerra E,Aloisi AL.Up-regulation of Trop-2 quantitatively stimulates human cancer growth..Oncogene2013;32:222-33

[13] De Vita VT, Lawrence TS, Rosenberg SA. De Vita, Hellman & Rosenberg’s Cancer: Principles & Practice of Oncology. Available from: http://www.kubalibri.cz/files/176---DeVita,-Hellman,-and-Rosenberg-s-Cancer---Principles---Practice-of-Oncology.pdf. [Last accessed on 9 Apr 2019]

[14] Tomasetti C,Vogelstein B.Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention..Science2017;355:1330-4 PMCID:PMC5852673

[15] Trerotola M,Simeone P.Epigenetic inheritance and the missing heritability..Hum Genomics2015;9:17 PMCID:PMC4517414

[16] Simeone P.Epigenetic heredity of human height..Physiol Rep2014;2:e12047 PMCID:PMC4208652

[17] Patel JN,Dunnenberger HM.Value of supportive care pharmacogenomics in oncology practice..Oncologist2018;23:956-64 PMCID:PMC6156181

[18] Cascorbi I,Werk AN.Challenges in pharmacogenetics..Eur J Clin Pharmacol.2013;69 Suppl 1:17-23

[19] Garralda E,Lopez-Casas PP,Katz A.Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment..Clin Cancer Res2014;20:2476-84 PMCID:PMC4322867

[20] Gillis NK,Innocenti F.Clinical implementation of germ line cancer pharmacogenetic variants during the next-generation sequencing era..Clin Pharmacol Ther2014;95:269-80 PMCID:PMC4128332

[21] Adams DR.Next-generation sequencing to diagnose suspected genetic disorders..N Engl J Med2018;379:1353-62

[22] Hynes SO,James JA,Salto-Tellez M.Tissue-based next generation sequencing: application in a universal healthcare system..Br J Cancer2017;116:553-60 PMCID:PMC5344287

[23] Klotz U.The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications..Clin Pharmacokinet2007;46:271-9

[24] Evans WE.Pharmacogenomics: translating functional genomics into rational therapeutics..Science1999;286:487-91

[25] Pinto N,Dolan ME.Using germline genomics to individualize pediatric cancer treatments..Clin Cancer Res2012;18:2791-800 PMCID:PMC3354919

[26] Crona D.Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy?.Biomark Med2012;6:349-62 PMCID:PMC3704209

[27] Stadler ZK,Vijai J,Offit K.Cancer Genomics and Inherited Risk..Journal of Clinical Oncology2014;32:687-98 PMCID:PMC5795694

[28] Shimelis H,Hu C,Na J.Triple-negative breast cancer risk genes identified by multigene hereditary cancer panel testing..J Natl Cancer Inst2018;Epub ahead of print, DOI: 10.1093/jnci/djy106 PMCID:PMC6093350

[29] Tai YC,Parmigiani G.Breast cancer risk among male BRCA1 and BRCA2 mutation carriers..J Natl Cancer Inst2007;99:1811-4 PMCID:PMC2267289

[30] Mavaddat N,Frost D,Platte R.Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE..J Natl Cancer Inst2013;105:812-22

[31] Hahn SA,Ellis I,Rieder H.BRCA2 germline mutations in familial pancreatic carcinoma..JNCI Cancer Spectrum2003;95:214-21

[32] Rafnar T,Stacey SN,Sulem P.Association of BRCA2 K3326* with small cell lung cancer and squamous cell cancer of the skin..J Natl Cancer Inst2018;110:967-74 PMCID:PMC6136924

[33] Guerra E,Simeone P,Lattanzio R.p53, cathepsin D, Bcl-2 are joint prognostic indicators of breast cancer metastatic spreading..BMC Cancer2016;16:649 PMCID:PMC4991058

[34] Smith KL,Kauff N,Boyd J.BRCA mutations in women with ductal carcinoma in situ..Clin Cancer Res2007;13:4306-10

[35] Robson M,Senkus E,Domchek SM.Olaparib for metastatic breast cancer in patients with a germline BRCA mutation..N Engl J Med2017;377:1700

[36] Peeters M,Van Cutsem E,Zhang K.Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab..J Clin Oncol2013;31:759-65

[37] Jia Y,Park E,Manuia M.Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors..Nature2016;534:129-32 PMCID:PMC4929832

[38] Lee CK,Ding PN,Inoue A.Impact of specific epidermal growthfactor receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: a meta-analysis..J Clin Oncol2015;33:1958-65

[39] Sabapathy K.Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others..Nat Rev Clin Oncol2018;15:13-30

[40] Zirath H,Oliynyk G,Westermark UK.MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells..Proc Natl Acad Sci U S A2013;110:10258-63 PMCID:PMC3690852

[41] Mason KD,Scott CL,Cory S.In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas..Proc Natl Acad Sci U S A2008;105:17961-6 PMCID:PMC2582212

[42] Arango D,Wadler S,Augenlicht LH.c-myc/p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo..Cancer Res2001;61:4910-5

[43] Janku F,Westin SN,Naing A.PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations..J Clin Oncol2012;30:777-82 PMCID:PMC3295566

[44] Munoz DM,Li L,Korn JM.CRISPR screens provide a comprehensive assessment of cancer vulnerabilities but generate false-positive hits for highly amplified genomic regions..Cancer Discov2016;6:900-13

[45] Tzelepis K,De Braekeleer E,Metzakopian E.A CRISPR dropout screen identifies genetic vulnerabilities and therapeutic targets in acute myeloid leukemia..Cell Rep2016;17:1193-205 PMCID:PMC5081405

[46] Wang T,Hughes NW,Kendirli A.Gene essentiality profiling reveals gene networks and synthetic lethal interactions with oncogenic ras..Cell2017;168:890-903 PMCID:PMC5445660

[47] Shen H,Ferrari M.Nanovector delivery of siRNA for cancer therapy..Cancer Gene Ther2012;19:367-73 PMCID:PMC3842228

[48] Day FR,Helgason H,Finucane H.Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk..Nat Genet2017;49:834-41 PMCID:PMC5841952

[49] Dzobo K.Epigenomics-guided drug development: recent advances in solving the cancer treatment “jigsaw puzzle”..OMICS2019;23:70-85

[50] Ling A,Fessler J.More than fishing for a cure: the promises and pitfalls of high throughput cancer cell line screens..Pharmacol Ther2018;191:178-89

[51] Rubin AJ,Satpathy AT,Wu B.Coupled single-cell CRISPR screening and epigenomic profiling reveals causal gene regulatory networks..Cell2019;176:361-76 PMCID:PMC6329648

[52] Nijman SM.Synthetic lethality: general principles, utility and detection using genetic screens in human cells..FEBS Lett2011;585:1-6 PMCID:PMC3018572

[53] Srivas R,Yang CC,Li J.A network of conserved synthetic lethal interactions for exploration of precision cancer therapy..Mol Cell2016;63:514-25 PMCID:PMC5209245

[54] Dixon SJ,Baryshnikova A,Boone C.Systematic mapping of genetic interaction networks..Annu Rev Genet2009;43:601-25

[55] Mengwasser KE,Leng Y,Clairmont C.Genetic screens reveal FEN1 and APEX2 as BRCA2 synthetic lethal targets..Mol Cell2019;73:885-99

[56] Tharp AP,Hunt PA,Sonnenschein C.Bisphenol A alters the development of the rhesus monkey mammary gland..Proc Natl Acad Sci U S A2012;109:8190-5 PMCID:PMC3361442

[57] Carletti E,Alberti S.The forgotten variables of DNA array hybridization..Trends Biotechnol2006;24:443-8

[58] Kalemkerian GP,Kennedy EB,Donington J.Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American society of clinical oncology endorsement of the college of American pathologists/international association for the study of lung cancer/association for molecular pathology clinical practice guideline update..J Clin Oncol2018;36:911-9

[59] Antonia SJ,Daniel D,Murakami S.Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC..New England Journal of Medicine2018;379:2342-50

[60] Ortega VE.Pharmacogenetics: implications of race and ethnicity on defining genetic profiles for personalized medicine..J Allergy Clin Immunol2014;133:16-26 PMCID:PMC3933289

[61] Rabbani B,Akhondzadeh S,Mahdieh N.Next generation sequencing: implications in personalized medicine and pharmacogenomics..Mol Biosyst2016;12:1818-30

[62] Garraway LA.Genomics-driven oncology: framework for an emerging paradigm..J Clin Oncol2013;31:1806-14

[63] Dong L,Li A,Chen Y.Clinical next generation sequencing for precision medicine in cancer..Curr Genomics2015;16:253-63 PMCID:PMC4765520

[64] Filipski KK,Long R.Pharmacogenomics in oncology care..Front Genet2014;5:73 PMCID:PMC3986526

[65] Caudle KE,Hoffman JM,Whirl-Carrillo M.Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process..Curr Drug Metab2014;15:209-17 PMCID:PMC3977533

[66] Relling MV, Schwab M, Whirl-Carrillo M, Suarez-Kurtz G, Pui CH, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update. Clin Pharmacol Ther 2018. Available from: https://ascpt.onlinelibrary.wiley.com/doi/full/10.1002/cpt.1304. [Last accessed on 9 Apr 2019]

[67] Luzum JA,Elsey AR,Peterson JF.The pharmacogenomics research network translational pharmacogenetics program: outcomes and metrics of pharmacogenetic implementations across diverse healthcare systems..Clin Pharmacol Ther2017;102:502-10 PMCID:PMC5511786

[68] Romani A,Trerotola M.Detection and analysis of spliced chimeric mRNAs in sequence databanks..Nucleic Acids Res2003;31:1-8

[69] Plebani R,Trerotola M,Cantanelli P.Long-range transcriptome sequencing reveals cancer cell growth regulatory chimeric mRNA..Neoplasia2012;14:1087-96 PMCID:PMC3514740

[70] Alberti S.DNA methylation prevents transfection of genes for specific surface antigens..Proc Natl Acad Sci USA1988;85:8391-4 PMCID:PMC282463

[71] Alberti S,Herzenberg LA.DNA methylation prevents the amplification of TROP1, a tumor associated cell surface antigen gene..Proc Natl Acad Sci USA1994;91:5833-7 PMCID:PMC44091

[72] Nevedomskaya E,Zwart W.Genome-wide epigenetic profiling of breast cancer tumors treated with aromatase inhibitors..Genom Data2014;2:195-8 PMCID:PMC4536071

[73] Margulies M,Altman WE,Bader JS.Genome sequencing in microfabricated high-density picolitre reactors..Nature2005;437:376-80 PMCID:PMC1464427

[74] Voelkerding KV,Durtschi JD.Next-generation sequencing: from basic research to diagnostics..Clin Chem2009;55:641-58

[75] Kchouk M,Elloumi M.Generations of sequencing technologies: from first to next generation..Biol Med2017;9:8

[76] Besser J,Gerner-Smidt P,Trees E.Next-generation sequencing technologies and their application to the study and control of bacterial infections..Clin Microbiol Infect2018;24:335-41 PMCID:PMC5857210

[77] Norris AL,Fan Y,Timp W.Nanopore sequencing detects structural variants in cancer..Cancer Biol Ther2016;17:246-53 PMCID:PMC4848001

[78] Cao Y,Proos S,Srikumar S.A review on the applications of next generation sequencing technologies as applied to food-related microbiome studies..Front Microbiol2017;8:1829 PMCID:PMC5627019

[79] Simeone P.RE: HABP2 G534E mutation in familial nonmedullary thyroid cancer..J Natl Cancer Inst2016;108: PMCID:PMC5017948

[80] Herbst RS,Boshoff C.The biology and management of non-small cell lung cancer..Nature2018;553:446-54

[81] Rehm HL,Bayrak-Toydemir P,Brown KK.ACMG clinical laboratory standards for next-generation sequencing..Genet Med2013;15:733-47 PMCID:PMC4098820

[82] Dubbink HJ,Tops BB,Koljenovic S.Next generation diagnostic molecular pathology: critical appraisal of quality assurance in Europe..Mol Oncol2014;8:830-9 PMCID:PMC5528536

[83] Li MM,Duncavage EJ,Lindeman NI.Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the association for molecular pathology, American society of clinical oncology, and College of American pathologists..J Mol Diagn2017;19:4-23 PMCID:PMC5707196

[84] Schwarz UI,Kim RB.The role of next-generation sequencing in pharmacogenetics and pharmacogenomics..Cold Spring Harb Perspect Med2019;Epub ahead of print [PMID: 29844222 DOI: 10.1101/cshperspect.a033027]

[85] Chennagiri N,Frieden A,Lieber DS.Orthogonal NGS for high throughput clinical diagnostics..Sci Rep2016;6:24650 PMCID:PMC4836299

[86] Nasr AF,Palombo B,Alberti S.Mutations ofTP53 induce loss of DNA methylation and amplification of the TROP1 gene..Oncogene2003;22:1668-77

[87] Li Y,Levenson V,Simeone P.A seven-gene CpG-island methylation panel predicts breast cancer progression..BMC Cancer2015;15:417 PMCID:PMC4438505

[88] Lauschke VM.Requirements for comprehensive pharmacogenetic genotyping platforms..Pharmacogenomics2016;17:917-24

[89] Mandelker D,Ankala A,Bowser M.Navigating highly homologous genes in a molecular diagnostic setting: a resource for clinical next-generation sequencing..Genet Med2016;18:1282-9

[90] Rasmussen-Torvik LJ,Gordon AS,Basford MA.Design and anticipated outcomes of the eMERGE-PGx project: a multicenter pilot for preemptive pharmacogenomics in electronic health record systems..Clin Pharmacol Ther2014;96:482-9 PMCID:PMC4169732

[91] Chu WK,Lee HS,Bafna V.Ultraaccurate genome sequencing and haplotyping of single human cells..Proceedings of the National Academy of Sciences2017;114:12512-7 PMCID:PMC5703283

[92] Kim C,Sei E,Hartman J.Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing..Cell2018;173:879-93 PMCID:PMC6132060

[93] Zhou J,Zhang L,Ma Y.Combined single-cell profiling of lncRNAs and functional screening reveals that H19 is pivotal for embryonic hematopoietic stem cell development..Cell Stem Cell2019;24:285-98

[94] Irish JM,Nolan GP.Mapping normal and cancer cell signalling networks: towards single-cell proteomics..Nat Rev Cancer2006;6:146-55

[95] Treutlein B.Evaluation of Wu et al.: strengthening single-cell bioinformatic comparisons for improving organoid differentiation..Cell Stem Cell2019;24:343-4